BNP and NT-proBNP: Heart Failure Peptide Tests

Peptide Biomarkers in Diagnostics

1,586 patients enrolled

The Breathing Not Properly study enrolled 1,586 patients presenting with acute dyspnea to emergency departments and established BNP at 100 pg/mL as the diagnostic cutoff for heart failure, with 90% sensitivity and 76% specificity.

Maisel et al., NEJM, 2002

Maisel et al., NEJM, 2002

View as image

When the heart fails, it sends a peptide distress signal. Cardiac myocytes stretched by volume overload or pressure overload produce proBNP, a 108-amino-acid precursor that is cleaved into two fragments: the biologically active BNP (B-type natriuretic peptide, 32 amino acids) and the biologically inactive NT-proBNP (N-terminal proBNP, 76 amino acids). Both circulate in blood and both can be measured. Together, they are the most widely used biomarkers in cardiology, with clinical guidelines from the ESC, ACC/AHA, and multiple national societies recommending their measurement in any patient presenting with symptoms suggestive of heart failure.^[1] This article explains the biology of these peptide biomarkers, the diagnostic cutoffs used in clinical practice, the differences between BNP and NT-proBNP, and the limitations clinicians face when interpreting results. For the broader landscape of peptide biomarkers, see the pillar article on chromogranin A: the neuroendocrine tumor peptide marker. For related biomarker topics, see amyloid-beta as an Alzheimer's biomarker.

How the heart produces BNP

BNP was originally called "brain natriuretic peptide" because it was first isolated from porcine brain tissue in 1988 by Sudoh et al. Despite the name, the heart is by far the primary source in humans. Cardiac ventricles produce the vast majority of circulating BNP in response to myocardial wall stress.

The production pathway begins with a 134-amino-acid preproBNP molecule. A signal peptide is cleaved to produce proBNP (108 amino acids), which is then cleaved by the enzymes corin and furin into two fragments: the active hormone BNP (amino acids 77-108, 32 residues) and the inactive N-terminal fragment NT-proBNP (amino acids 1-76, 76 residues). Both fragments are released into the bloodstream in equimolar amounts, but their pharmacokinetics differ substantially.^[3]

BNP is biologically active. It binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and producing cGMP. This triggers vasodilation, natriuresis (sodium excretion), diuresis (water excretion), and suppression of the renin-angiotensin-aldosterone system (RAAS). BNP is the heart's counter-regulatory response to volume overload: when the ventricle is stretched, BNP tries to reduce blood volume and blood pressure.

NT-proBNP has no known biological activity. It serves purely as a biomarker. Its clinical value comes from its pharmacokinetic properties: NT-proBNP has a half-life of approximately 120 minutes, six times longer than BNP's 20-minute half-life. This longer half-life means NT-proBNP accumulates to higher circulating concentrations and is less affected by short-term fluctuations, making it a more stable measurement target for clinical laboratories.^[3]

The Breathing Not Properly study: establishing BNP as a diagnostic tool

The clinical utility of BNP for diagnosing heart failure was established by the landmark Breathing Not Properly Multinational Study. Maisel et al. (2002) enrolled 1,586 patients who presented to emergency departments with acute dyspnea (shortness of breath). The central question was whether a single blood test could distinguish heart failure from other causes of dyspnea, including pneumonia, COPD exacerbation, and pulmonary embolism.

The results were definitive. At a cutoff of 100 pg/mL, BNP had 90% sensitivity and 76% specificity for diagnosing acute heart failure. The negative predictive value was 89%, meaning that a BNP below 100 pg/mL made heart failure unlikely enough to direct the clinical workup elsewhere. BNP performed better than clinical judgment alone, with the area under the receiver operating characteristic curve (AUC) of 0.91 compared to 0.86 for emergency physician assessment.^[2]

This study transformed emergency medicine practice. Before BNP testing, the diagnosis of heart failure in patients with acute dyspnea relied on clinical assessment, chest X-ray, and echocardiography, a combination that was time-consuming and often ambiguous. An elderly patient with COPD and peripheral edema could easily be misdiagnosed as having a COPD exacerbation when heart failure was the actual cause, or vice versa. BNP added an objective biochemical measure that could be obtained in minutes from a simple blood draw. Subsequent cost-effectiveness analyses showed that BNP-guided emergency department evaluation reduced time to treatment, length of hospital stay, and overall treatment costs compared to standard clinical assessment alone.

Diagnostic cutoffs: the numbers clinicians use

Current clinical guidelines use different cutoffs for BNP and NT-proBNP, for acute and non-acute settings, and increasingly stratify by age.

For ruling OUT heart failure:

• BNP less than 100 pg/mL in the acute setting, less than 35 pg/mL in the non-acute setting
• NT-proBNP less than 300 pg/mL in the acute setting, less than 125 pg/mL in the non-acute setting

Age-stratified rule-IN thresholds for NT-proBNP (acute setting):

• Under 50 years: greater than 450 pg/mL
• 50-75 years: greater than 900 pg/mL
• Over 75 years: greater than 1,800 pg/mL

These age adjustments exist because NT-proBNP concentrations increase with normal aging, driven by age-related declines in renal clearance and increases in cardiac wall stress from arterial stiffening. Using a single threshold across all ages would produce unacceptable rates of false positives in elderly patients and false negatives in younger patients.^[1]

A 2025 consensus guideline from the Eurasian Society of Heart Failure and the Turkish Association of Family Medicine emphasized that natriuretic peptide testing belongs in primary care, not just emergency departments. The guideline recommended NT-proBNP as the first-line test for any patient with unexplained dyspnea, fatigue, or peripheral edema, with values below the rule-out threshold sufficient to redirect the workup without echocardiography.^[1]

BNP vs NT-proBNP: which test and when

Both tests measure the same physiological signal, myocardial wall stress, but their different pharmacokinetics create different clinical profiles.

BNP advantages: Shorter half-life makes it more responsive to acute changes. Better for monitoring rapid response to acute heart failure treatment (e.g., diuretic response). Not significantly affected by renal function until GFR drops below 30 mL/min.

NT-proBNP advantages: Longer half-life provides more stable concentrations and better assay precision. Single standardized assay platform (Roche Elecsys) reduces inter-laboratory variability. Higher circulating concentrations are easier to measure accurately. Better characterized age-stratified reference ranges.

Key interaction with neprilysin inhibitors: Sacubitril/valsartan (Entresto), a cornerstone heart failure therapy, works by inhibiting neprilysin, the enzyme that degrades BNP. This means patients on sacubitril/valsartan have artificially elevated BNP levels that do not reflect worsening heart failure. NT-proBNP is not a substrate for neprilysin and is unaffected by this drug. Nishikimi et al. (2022) explicitly addressed this: in the era of sacubitril/valsartan therapy, NT-proBNP is the preferred biomarker for monitoring because BNP levels become unreliable.^[3]

The HFpEF challenge

Heart failure with preserved ejection fraction (HFpEF) accounts for roughly half of all heart failure cases. In HFpEF, the heart's pumping function appears normal (ejection fraction over 50%), but the ventricle is stiff and does not fill properly. BNP and NT-proBNP levels are often lower in HFpEF than in heart failure with reduced ejection fraction (HFrEF), creating a diagnostic gray zone.

Kanyal et al. (2025) reviewed NT-proBNP specifically as a biomarker for HFpEF, noting that standard cutoffs optimized for HFrEF miss a significant fraction of HFpEF cases. The peptide retains diagnostic value but at lower discriminatory power. Several groups have proposed HFpEF-specific cutoffs, but no consensus has emerged.^[7]

Ammar et al. (2025) conducted a systematic review of BNP and NT-proBNP as prognostic biomarkers specifically in HFpEF patients. Both peptides predicted adverse outcomes including hospitalization and mortality, confirming that even in HFpEF, higher natriuretic peptide levels signal worse prognosis. The review noted substantial heterogeneity across studies in the cutoffs used, reflecting the ongoing uncertainty about optimal thresholds for this population.^[4]

Natriuretic peptides and GLP-1 agonists

An unexpected finding emerged from the STEP-HFpEF clinical trial program. Petrie et al. (2024) reported that semaglutide reduced NT-proBNP levels by 20-25% in patients with obesity-related HFpEF. The reduction was associated with improvements in symptoms, physical limitations, and exercise capacity. The mechanism likely involves weight loss reducing cardiac preload and afterload, but direct cardiac effects of GLP-1 signaling on myocardial metabolism cannot be excluded.^[5]

This finding illustrates how NT-proBNP functions as both a diagnostic tool and a treatment response marker. If a therapy reduces wall stress, NT-proBNP levels decline proportionally. Serial NT-proBNP measurement can track whether a treatment is working without requiring repeat echocardiography.

Point-of-care testing: from the lab to the bedside

Traditional BNP and NT-proBNP measurement requires sending blood samples to a central laboratory, with turnaround times of 30 minutes to several hours. Point-of-care (POC) assays bring the test to the patient's bedside.

Belik et al. (2025) evaluated a POC NT-proBNP assay for heart failure management and found analytical performance comparable to central laboratory analyzers, with rapid results available in under 15 minutes. The clinical impact is greatest in primary care and rural settings where central laboratory access is limited.^[6]

POC testing also enables telemedicine-guided heart failure management. Durrington et al. (2025) described NT-proBNP and BNP POC testing in pulmonary arterial hypertension, where remote monitoring of natriuretic peptide levels could detect clinical deterioration before symptoms become severe enough to prompt hospital visits.^[8]

Beyond heart failure: expanding diagnostic applications

While heart failure is the primary clinical application, natriuretic peptides have diagnostic and prognostic value across cardiovascular medicine.

Queiroz et al. (2026) systematically reviewed NT-proBNP as a prognostic biomarker for cardiac surgery outcomes, finding that preoperative NT-proBNP levels predicted postoperative complications including mortality, acute kidney injury, and prolonged ICU stay. Elevated preoperative NT-proBNP identifies patients whose hearts are already under stress before the additional insult of cardiac surgery.^[9]

Ludwikowska et al. (2024) reviewed BNP and NT-proBNP in pediatric patients, noting that reference ranges differ substantially from adults and that applications include monitoring congenital heart disease, Kawasaki disease, and cardiotoxicity from chemotherapy. Pediatric natriuretic peptide interpretation requires age-specific and context-specific thresholds that are less well established than adult values.^[10]

Confounders and limitations

Natriuretic peptide levels are influenced by several factors beyond cardiac function.

Obesity reduces BNP and NT-proBNP levels. Adipose tissue expresses natriuretic peptide clearance receptors (NPR-C), increasing removal of BNP from the circulation. This means obese patients can have falsely low natriuretic peptide levels despite significant heart failure. The combination of obesity and HFpEF, two conditions that independently lower BNP, creates a particularly challenging diagnostic scenario.

Renal function affects NT-proBNP more than BNP. NT-proBNP is cleared primarily by renal filtration, so reduced kidney function elevates NT-proBNP levels independently of cardiac status. In patients with chronic kidney disease, NT-proBNP levels must be interpreted with higher effective cutoffs.

Age and sex both influence baseline levels. Women have higher natriuretic peptide levels than men at any given level of cardiac function. Older adults have higher levels than younger adults. Age-stratified cutoffs partially address this but remain imperfect.

Atrial fibrillation elevates natriuretic peptides through atrial stretch, independent of heart failure. In patients with known atrial fibrillation, elevated BNP or NT-proBNP does not necessarily indicate heart failure.

Sepsis and critical illness can elevate natriuretic peptides through myocardial dysfunction, inflammatory cytokine-driven cardiomyocyte stretch, and renal impairment. In the ICU setting, elevated BNP or NT-proBNP requires careful interpretation alongside other biomarkers like procalcitonin and troponin. For the related metabolic biomarker that distinguishes type 1 from type 2 diabetes, see C-peptide.

These confounders mean natriuretic peptide levels are most useful for ruling out heart failure (very high negative predictive value at low cutoffs) and least reliable for confirming it in patients with multiple comorbidities. The test changes the probability of diagnosis; it does not provide it. A low BNP in the emergency department is among the most clinically actionable biomarker results in medicine. An elevated BNP in a 75-year-old with obesity, renal impairment, and atrial fibrillation requires clinical judgment that no single number can replace.

The Bottom Line

BNP and NT-proBNP are the most widely used peptide biomarkers in medicine, measured hundreds of millions of times annually to diagnose and monitor heart failure. The Breathing Not Properly study established BNP at 100 pg/mL as the emergency department diagnostic threshold with 90% sensitivity. Current guidelines use age-stratified cutoffs for NT-proBNP. The introduction of sacubitril/valsartan has shifted clinical practice toward NT-proBNP because BNP levels become unreliable on neprilysin inhibitor therapy. HFpEF remains a diagnostic challenge where natriuretic peptide levels are often in a gray zone. Point-of-care assays are expanding access beyond central laboratories to primary care and remote monitoring settings.

Frequently Asked Questions

What is BNP and what does it measure?

BNP (B-type natriuretic peptide) is a 32-amino-acid hormone released by cardiac ventricles when they are stretched by volume or pressure overload. Blood levels of BNP reflect the degree of myocardial wall stress. A BNP level above 100 pg/mL in a patient with acute shortness of breath has 90% sensitivity for heart failure diagnosis (Maisel et al., NEJM, 2002).^[2]

What is the difference between BNP and NT-proBNP?

Both come from the same precursor molecule (proBNP), released when the heart is under stress. BNP is the active hormone (32 amino acids, 20-minute half-life) that lowers blood pressure and promotes sodium excretion. NT-proBNP is the inactive fragment (76 amino acids, 120-minute half-life) that serves purely as a biomarker. NT-proBNP is preferred for patients on sacubitril/valsartan because neprilysin inhibitors artificially raise BNP but not NT-proBNP.^[3]

What is a normal BNP level?

In non-acute settings, BNP below 35 pg/mL and NT-proBNP below 125 pg/mL are considered normal and effectively rule out heart failure. In the emergency department, BNP below 100 pg/mL and NT-proBNP below 300 pg/mL are the rule-out thresholds. Values above these levels require further evaluation but do not by themselves confirm heart failure, as obesity, renal function, age, and atrial fibrillation all influence levels.^[1]

Can BNP diagnose heart failure with preserved ejection fraction?

BNP and NT-proBNP retain diagnostic value in HFpEF but at lower discriminatory power than in HFrEF. Natriuretic peptide levels are typically lower in HFpEF, often falling into a diagnostic gray zone. Ammar et al. (2025) confirmed that both peptides still predict adverse outcomes in HFpEF patients, but optimal diagnostic cutoffs for this specific population remain under debate.^[4]

Why does obesity lower BNP levels?

Adipose tissue expresses natriuretic peptide clearance receptors (NPR-C) that remove BNP from the circulation. More body fat means more clearance receptors, leading to lower circulating BNP and NT-proBNP levels. This creates a diagnostic challenge: obese patients with heart failure may have falsely reassuring natriuretic peptide levels. Clinicians must use lower diagnostic thresholds or rely more heavily on clinical assessment in obese patients.

Does semaglutide affect BNP or NT-proBNP levels?

In the STEP-HFpEF program, semaglutide reduced NT-proBNP levels by 20-25% in patients with obesity-related HFpEF, associated with symptom improvement and better exercise capacity. The reduction likely reflects decreased cardiac wall stress from weight loss and possibly direct cardiac effects of GLP-1 receptor signaling (Petrie et al., JACC Heart Failure, 2024).^[5]